JNJ-Q2
Clinical data | |
---|---|
Routes of administration | Oral, IV |
Identifiers | |
| |
ChemSpider | 9721013 |
Chemical and physical data | |
Formula | C21H23F2N3O4 |
Molar mass | 419.42 g/mol |
3D model (Jmol) | Interactive image |
| |
|
JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.[2][3]
Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.[4]
References
- ↑ "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.
- ↑ Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrob. Agents Chemother. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.
- ↑ Morrow BJ, He W, Amsler KM, et al. (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrob. Agents Chemother. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.
- ↑ "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.
This article is issued from Wikipedia - version of the 6/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.